Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11)

English version České info

Background:
Antiretroviral therapy (ART) has major benefits during pregnancy, both for maternal health and to prevent mother-to-child transmission of HIV. Safety issues, including teratogenic risk, need to be evaluated. We estimated the prevalence of birth defects in children born to HIV-infected women receiving ART during pregnancy, and assessed the independent association of birth defects with each antiretroviral (ARV) drug used.

Methods and Findings:
The French Perinatal Cohort prospectively enrolls HIV-infected women delivering in 90 centers throughout France. Children are followed by pediatricians until 2 y of age according to national guidelines.

We included 13,124 live births between 1994 and 2010, among which, 42% (n = 5,388) were exposed to ART in the first trimester of pregnancy. Birth defects were studied using both European Surveillance of Congenital Anomalies (EUROCAT) and Metropolitan Atlanta Congenital Defects Program (MACDP) classifications; associations with ART were evaluated using univariate and multivariate logistic regressions. Correction for multiple comparisons was not performed because the analyses were based on hypotheses emanating from previous findings in the literature and the robustness of the findings of the current study. The prevalence of birth defects was 4.4% (95% CI 4.0%–4.7%), according to the EUROCAT classification. In multivariate analysis adjusting for other ARV drugs, maternal age, geographical origin, intravenous drug use, and type of maternity center, a significant association was found between exposure to zidovudine in the first trimester and congenital heart defects: 2.3% (74/3,267), adjusted odds ratio (AOR) = 2.2 (95% CI 1.3–3.7), p = 0.003, absolute risk difference attributed to zidovudine +1.2% (95% CI +0.5; +1.9%). Didanosine and indinavir were associated with head and neck defects, respectively: 0.5%, AOR = 3.4 (95% CI 1.1–10.4), p = 0.04; 0.9%, AOR = 3.8 (95% CI 1.1–13.8), p = 0.04. We found a significant association between efavirenz and neurological defects (n = 4) using the MACDP classification: AOR = 3.0 (95% CI 1.1–8.5), p = 0.04, absolute risk +0.7% (95% CI +0.07%; +1.3%). But the association was not significant using the less inclusive EUROCAT classification: AOR = 2.1 (95% CI 0.7–5.9), p = 0.16. No association was found between birth defects and lopinavir or ritonavir with a power >85% for an odds ratio of 1.5, nor for nevirapine, tenofovir, stavudine, or abacavir with a power >70%. Limitations of the present study were the absence of data on termination of pregnancy, stillbirths, tobacco and alcohol intake, and concomitant medication.

Conclusions:
We found a specific association between in utero exposure to zidovudine and heart defects; the mechanisms need to be elucidated. The association between efavirenz and neurological defects must be interpreted with caution. For the other drugs not associated with birth defects, the results were reassuring. Finally, whatever the impact that some ARV drugs may have on birth defects, it is surpassed by the major role of ART in the successful prevention of mother-to-child transmission of HIV.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Association between Prenatal Exposure to Antiretroviral Therapy and Birth Defects: An Analysis of the French Perinatal Cohort Study (ANRS CO1/CO11). PLoS Med 11(4): e32767. doi:10.1371/journal.pmed.1001635
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001635

Souhrn

Zdroje

1. WarszawskiJ, TubianaR, Le ChenadecJ, BlancheS, TeglasJP, et al. (2008) Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort. AIDS 22: 289–299.

2. European Collaborative Study (2005) Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis 40: 458–465.

3. CooperER, CharuratM, MofensonL, HansonIC, PittJ, et al. (2002) Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr 29: 484–494.

4. Delfraissy JF (2004) Prise en charge thérapeutique des personnes infectées par le VIH. Rapport 2004. Recommandations du groupe d'experts. Paris: Flammarion Médecine-Sciences.

5. BlancheS, TardieuM, BenhammouV, WarszawskiJ, RustinP, et al. (2006) Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS 20: 1685–1690.

6. ThorneC, NewellML (2007) Safety of agents used to prevent mother-to-child transmission of HIV: is there any cause for concern? Drug Saf 30: 203–213.

7. BriandN, MandelbrotL, Le ChenadecJ, TubianaR, TeglasJP, et al. (2009) No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS 23: 1235–1243.

8. JaoJ, AbramsEJ (2013) Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants. Pediatr Infect Dis J E-pub ahead of print. doi:10.1097/INF.0000000000000224

9. Bristol-Myers Squibb Company (2006) Sustiva (efavirenz) capsules and tablets leaflet. Available: http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021360s014lbl.pdf. Accessed 6 July 2013.

10. FordN, CalmyA, MofensonL (2011) Safety of efavirenz in the first trimester of pregnancy: an updated systematic review and meta-analysis. AIDS 25: 2301–2304.

11. BroglySB, AbzugMJ, WattsDH, CunninghamCK, WilliamsPL, et al. (2010) Birth defects among children born to human immunodeficiency virus-infected women: pediatric AIDS clinical trials protocols 219 and 219C. Pediatr Infect Dis J 29: 721–727.

12. KnappKM, BroglySB, MuenzDG, SpiegelHM, ConwayDH, et al. (2012) Prevalence of congenital anomalies in infants with in utero exposure to antiretrovirals. Pediatr Infect Dis J 31: 164–170.

13. Antiretroviral Pregnancy Registry Steering Committee (2013) The Antiretroviral Pregnancy Registry: interim report—1 January 1989 through 31 July 2013. Available: http://www.apregistry.com/forms/interim_report.pdf. Accessed 27 January 2014.

14. WattsDH, HuangS, CulnaneM, KaiserKA, ScheuerleA, et al. (2011) Birth defects among a cohort of infants born to HIV-infected women on antiretroviral medication. J Perinat Med 39: 163–170.

15. FloridiaM, MastroiacovoP, TamburriniE, TibaldiC, TodrosT, et al. (2013) Birth defects in a national cohort of pregnant women with HIV infection in Italy, 2001–2011. BJOG 120: 1466–1475.

16. Fernandez IbietaM, Ramos AmadorJT, Bellon CanoJM, Gonzalez-TomeMI, Guillen MartinS, et al. (2009) Birth defects in a cohort of uninfected children born to HIV-infected women. An Pediatr (Barc) 70: 253–264.

17. TownsendCL, WilleyBA, Cortina-BorjaM, PeckhamCS, TookeyPA (2009) Antiretroviral therapy and congenital abnormalities in infants born to HIV-infected women in the UK and Ireland, 1990–2007. AIDS 23: 519–524.

18. PatelD, ThorneC, FioreS, NewellML (2005) Does highly active antiretroviral therapy increase the risk of congenital abnormalities in HIV-infected women? J Acquir Immune Defic Syndr 40: 116–118.

19. NewschafferCJ, CocroftJ, AndersonCE, HauckWW, TurnerBJ (2000) Prenatal zidovudine use and congenital anomalies in a medicaid population. J Acquir Immune Defic Syndr 24: 249–256.

20. Yeni P, editor(2006) Prise en charge médicale des personnes infectées par le VIH. Recommandations du groupe d'experts.: Flammarion, Médecine-Sciences.

21. MayauxMJ, TeglasJP, BlancheS (2003) Characteristics of HIV-infected women who do not receive preventive antiretroviral therapy in the French Perinatal Cohort. J Acquir Immune Defic Syndr 34: 338–343.

22. EUROCAT (2005) EUROCAT Guide 1.3 and reference documents. Instructions for the Registration and Surveillance of Congenital Anomalies. Available at: http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf last accessed 01/27/2014

23. EUROCAT (2012) Coding of EUROCAT Subgroups of Congenital Anomalies (Version 2012). Available at: http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf last accessed 01/27/2014

24. MACDP (2007) Birth Defects and Genetic Diseases Branch 6-digit code for Reportable Congenital Anomalies.Available at: http://www.cdc.gov/ncbddd/birthdefects/documents/MACDPcode0807.pdf last accessed 01/27/2014

25. ScheuerleA, TilsonH (2002) Birth defect classification by organ system: a novel approach to heighten teratogenic signalling in a pregnancy registry. Pharmacoepidemiol Drug Saf 11: 465–475.

26. StataCorporation (2009) Stata 11.0 for Windows. College Station, Texas: Stata Corporation

27. JoaoEC, CalvetGA, KraussMR, Freimanis HanceL, OrtizJ, et al. (2010) Maternal antiretroviral use during pregnancy and infant congenital anomalies: the NISDI perinatal study. J Acquir Immune Defic Syndr 53: 176–185.

28. DuZD, RoguinN, BarakM, BihariSG, Ben-ElishaM (1996) High prevalence of muscular ventricular septal defect in preterm neonates. Am J Cardiol 78: 1183–1185.

29. LaasE, LelongN, ThieulinAC, HouyelL, BonnetD, et al. (2012) Preterm Birth and Congenital Heart Defects: A Population-based Study. Pediatrics Oct;130(4): e829–37.

30. Yeni P (2010) Prise en charge médicale des personnes infectées par le VIH: rapport 2010—Recommandations du groupe d'experts. Paris: La Documentation Française.

31. CzeizelAE, RockenbauerM, SorensenHT, OlsenJ (2001) The teratogenic risk of trimethoprim-sulfonamides: a population based case-control study. Reprod Toxicol 15: 637–646.

32. FornaF, McConnellM, KitabireFN, HomsyJ, BrooksJT, et al. (2006) Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings. AIDS Rev 8: 24–36.

33. JungmannEM, MerceyD, DeRuiterA, EdwardsS, DonoghueS, et al. (2001) Is first trimester exposure to the combination of antiretroviral therapy and folate antagonists a risk factor for congenital abnormalities? Sex Transm Infect 77: 441–443.

34. RichardsonMP, OsrinD, DonaghyS, BrownNA, HayP, et al. (2000) Spinal malformations in the fetuses of HIV infected women receiving combination antiretroviral therapy and co-trimoxazole. Eur J Obstet Gynecol Reprod Biol 93: 215–217.

35. LipshultzSE, ShearerWT, ThompsonB, RichKC, ChengI, et al. (2011) Cardiac effects of antiretroviral therapy in HIV-negative infants born to HIV-positive mothers: NHLBI CHAART-1 (National Heart, Lung, and Blood Institute Cardiovascular Status of HAART Therapy in HIV-Exposed Infants and Children cohort study). J Am Coll Cardiol 57: 76–85.

36. DesaiVG, LeeT, MolandCL, BranhamWS, MittelstaedtRA, et al. (2012) Evaluation of hepatic mitochondria and hematological parameters in zidovudine-treated B6C3F(1) mice. AIDS Res Treat 2012: 317695.

37. EkoueviDK, CoffiePA, OuattaraE, MohR, Amani-BosseC, et al. (2011) Pregnancy outcomes in women exposed to efavirenz and nevirapine: an appraisal of the IeDEA West Africa and ANRS Databases, Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr 56: 183–187.

38. HouyelL, KhoshnoodB, AndersonRH, LelongN, ThieulinAC, et al. (2012) Population-based evaluation of a suggested anatomic and clinical classification of congenital heart defects based on the International Paediatric and Congenital Cardiac Code. Orphanet J Rare Dis 6: 64.

39. World Health Organization (2013) Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Available: http://www.who.int/hiv/pub/guidelines/arv2013/download/en/index.html. Accessed 27 January 2014.

40. FundaroC, GenoveseO, RendeliC, TamburriniE, SalvaggioE (2002) Myelomeningocele in a child with intrauterine exposure to efavirenz. AIDS 16: 299–300.

41. SaitohA, HullAD, FranklinP, SpectorSA (2005) Myelomeningocele in an infant with intrauterine exposure to efavirenz. J Perinatol 25: 555–556.

42. Panel on Treatment of HIV-Infected Pregnant Women and Prevention of Perinatal Transmission (2012) Recommendations for use of antiretroviral drugs in pregnant HIV-1-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available: http://aidsinfo.nih.gov/guidelines/html/3/perinatal-guidelines/0. Accessed 27 January 2014.

43. RieckeK, SchulzTG, ShakibaeiM, KrauseB, ChahoudI, et al. (2000) Developmental toxicity of the HIV-protease inhibitor indinavir in rats. Teratology 62: 291–300.

44. EUROCAT (2012) Prevalence tables. Available: http://www.eurocat-network.eu/accessprevalencedata/prevalencetables. Accessed 27 January 2014.

45. RothmanKJ (1990) No adjustments are needed for multiple comparisons. Epidemiology 1: 43–46.